Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) EBT Margin (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed EBT Margin for 12 consecutive years, with 72319.9% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 11283501.0% year-over-year to 72319.9%, compared with a TTM value of 1768.07% through Dec 2025, down 71437.0%, and an annual FY2025 reading of 26284.04%, down 2523033.0% over the prior year.
  • EBT Margin was 72319.9% for Q4 2025 at Abvc Biopharma, up from 161.69% in the prior quarter.
  • Across five years, EBT Margin topped out at 72319.9% in Q4 2025 and bottomed at 242959.92% in Q1 2024.
  • Average EBT Margin over 5 years is 16078.54%, with a median of 1233.94% recorded in 2023.
  • The sharpest move saw EBT Margin crashed -24148085bps in 2024, then soared 24336177bps in 2025.
  • Year by year, EBT Margin stood at 15585.03% in 2021, then plummeted by -104bps to 600.69% in 2022, then crashed by -3937bps to 24249.38% in 2023, then crashed by -67bps to 40515.11% in 2024, then soared by 279bps to 72319.9% in 2025.
  • Business Quant data shows EBT Margin for ABVC at 72319.9% in Q4 2025, 161.69% in Q3 2025, and 1784.37% in Q2 2025.